<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01106053</url>
  </required_header>
  <id_info>
    <org_study_id>NEDA-Pramipexole</org_study_id>
    <nct_id>NCT01106053</nct_id>
  </id_info>
  <brief_title>Pramipexole for Binge Eating Disorder</brief_title>
  <official_title>An Exploration of the Effects of the Dopamine Agonist Pramipexole on Binge Antecedants, Binge Frequency, and Weight in Binge Eating Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuropsychiatric Research Institute, Fargo, North Dakota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neuropsychiatric Research Institute, Fargo, North Dakota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to evaluate the effects that the drug pramipexole has on mood,
      food craving, and other behaviors that may be related to binge eating disorder.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No participants were recruited and study has been closed.
  </why_stopped>
  <start_date>April 2010</start_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of binge eating</measure>
    <time_frame>Baseline followed by weekly during the seven week protocol</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>Baseline followed by weekly during the seven week protocol</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and extent of craving for food using validated instruments</measure>
    <time_frame>Baseline followed by weekly during the seven week protocol</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of mood ratings using a validated instrument</measure>
    <time_frame>Baseline followed by weekly during the seven week protocol</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Binge Eating Disorder</condition>
  <arm_group>
    <arm_group_label>Pramipexole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label trial of pramipexole.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pramipexole</intervention_name>
    <description>Pramipexole tablet titrated up to a maximum dosage of 0.5 mg three times daily (1.5 mg/day).</description>
    <arm_group_label>Pramipexole</arm_group_label>
    <other_name>Mirapex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  Age 18-50 years

          -  Women of child-bearing potential and males must agree to practice an accepted method
             of birth control. All women must have a negative pregnancy test at baseline.

          -  Good general health as demonstrated by history and physical examination.

          -  Body mass index of 30 kg/m2 or higher at the screening visit.

          -  Meet criteria for binge eating disorder as assessed through the SCID-1 and EDE.

        Exclusion Criteria:

          -  Subjects with any unstable medical condition, or any current or past medical condition
             which in the opinion of the study physician and/or the principal investigator may
             increase the risks associated with pramipexole and study participation. Medical
             appropriateness will be determined through history and physical exam.

          -  Subjects with any current Axis I psychiatric diagnosis as determined through the
             Structured Clinical Interview for DSM-IV for Axis I disorders (SCID-1) interview
             (aside from BED).

          -  Subjects with a Hamilton Depression Rating Scale score greater than or equal to 12 at
             the screening visit.

          -  Subjects who report any history of hallucinations or delusions.

          -  Participants taking an antidepressant or other regularly used psychotropic medication
             which may confound the study results

          -  Subjects with any current or history of an impulse control spectrum disorder, other
             than binge eating disorder,(such as pathological gambling, compulsive shopping, etc.)
             at screening as determined by the Structured Clinical Interview for DSM-IV Impulse
             Control Module.

          -  Subjects with any history of suicide attempts or current suicidal ideations.

          -  Subjects that have used tobacco products on a routine basis within the past six
             months.

          -  Subjects enrolled in any formal treatment programs or research protocols for binge
             eating disorder at present, or within the past 30 days.

          -  Subjects routinely taking any medication known to produce weight change (ex.
             olanzapine, amitriptyline, steroid medications, etc., other than oral contraceptives,
             stable thyroid replacement drugs, etc.), or medications with drug-drug interactions
             with pramipexole.

          -  Subjects who are currently breast-feeding.

          -  Subjects who have participated in an investigational drug trial in the past 30 days.

          -  Subjects who meet DSM IV-TR criteria for alcohol or drug abuse in the past year.

          -  Subjects with an allergy to pramipexole or tablet constituents.

          -  Subjects with hepatic dysfunction as determined through a hepatic panel obtained at
             the screening visit.

          -  Subjects with an elevated blood pressure or pulse at screening (140/90 mmHg or above
             or pulse of greater than 100 beats/minute after being seated and stationary for at
             least five minutes, or as determined at the discretion of the study physician and/or
             principal investigator) or history of serious cardiac events (myocardial infarction,
             arrhythmia, stroke, etc).

          -  Subjects with a history of renal dysfunction or with a creatinine clearance of less
             than 60 ml/min based upon a serum creatinine obtained during screening and as
             calculated with the Cockroft and Gault equation.

          -  Subjects with a positive urine drug screen.

          -  Any participant with Parkinson's disease or symptoms suggestive of probable
             Parkinson's disease.

          -  Subjects who have an Epworth Sleep Scale (ESS) score of &gt;7 at screening. ESS scores &gt;
             7 have been associated with an increased risk of sleep attacks (Plowman et al., 2005).

          -  Any participant who demonstrates clinically significant orthostatic blood pressure
             changes or is symptomatic during the screening visit, as defined under &quot;orthostatic
             blood pressure monitoring.&quot;

          -  History of bariatric surgery.

          -  Participants who report a history of obstructive sleep apnea, excessive fatigue, or
             any sleep disorder which in the opinion of the principal investigator or study medical
             personnel would increase the participant's risk of experiencing excessive somnolence
             with pramipexole.

          -  Participant has had a change in medication regimen in the last month (dose, starting a
             new medication, or stopping a medication).

          -  Participant is employed by, or has an immediate family member employed by NRI.

          -  Participant has participated in a formal weight loss program in the last month (e.g.
             Weight Watchers, Jenny Craig, etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristine J Steffen, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neuropsychiatric Research Institute, Fargo, ND</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.nrifargo.com</url>
    <description>NRI website</description>
  </link>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2010</study_first_submitted>
  <study_first_submitted_qc>April 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2010</study_first_posted>
  <last_update_submitted>May 3, 2013</last_update_submitted>
  <last_update_submitted_qc>May 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Neuropsychiatric Research Institute, Fargo, North Dakota</investigator_affiliation>
    <investigator_full_name>Kristine Steffen</investigator_full_name>
    <investigator_title>Reseach Scientist</investigator_title>
  </responsible_party>
  <keyword>Binge eating disorder</keyword>
  <keyword>Food craving</keyword>
  <keyword>Obesity</keyword>
  <keyword>Pramipexole</keyword>
  <keyword>Mirapex</keyword>
  <keyword>Binge</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Feeding and Eating Disorders</mesh_term>
    <mesh_term>Binge-Eating Disorder</mesh_term>
    <mesh_term>Bulimia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pramipexole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

